Clinical and magnetic resonance imaging characteristics of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease
Main Article Content
Abstract
A cross-sectional study was conducted on 50 patients, including 42 cases of neuromyelitis optica spectrum disorder (NMOSD) positive for AQP4-IgG and 8 cases of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) positive for MOG-IgG at Hanoi Medical University Hospital, to compare clinical characteristics and magnetic resonance imaging (MRI) features between the two groups. NMOSD showed a higher female predominance (95.2% vs. 62.5%) and an older age at onset (44.9 vs. 27.9 years old). The mean EDSS score was higher in NMOSD (3.6 vs. 2.8). Simultaneous bilateral optic neuritis was more common in MOGAD (50% vs. 7.1%), whereas area postrema syndrome was observed only in NMOSD. On MRI, NMOSD demonstrated a higher frequency of longitudinally extensive transverse myelitis (LETM) (58.5% vs. 12.5%), along with features such as bright spotty lesions, periventricular white matter involvement, and brainstem lesions. In contrast, MOGAD tended to show predominant anterior optic nerve involvement and perineural enhancement (25% vs. 2.4%). NMOSD and MOGAD exhibit distinct clinical and MRI features, which may support differential diagnosis in clinical practice.
Article Details
Keywords
NMOSD, MOGAD, Aquaporin-4, Anti MOG antibody, magnetic resonance imaging, optic neuritis
References
2. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53(5):1107-1107. doi:10.1212/WNL.53.5.1107
3. Moheb N, Chen JJ. The neuro-ophthalmological manifestations of NMOSD and MOGAD-a comprehensive review. Eye. 2023;37(12):2391-2398. doi:10.1038/s41433-023-02477-0
4. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology. 2015;84(11):1165-1173. doi:10.1212/WNL.0000000000001367
5. Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020;11:501. doi:10.3389/fneur.2020.00501
6. Nguyễn Văn Tuận, Nguyễn Văn Sỹ. Đặc điểm lâm sàng của phổ bệnh viêm tủy thị thần kinh. Tạp chí Thần kinh học Việt Nam. 2022;520(1A). doi:10.51298/vmj.v520i1.3778
7. Wingerchuk DM. Neuromyelitis optica: Effect of gender. J Neurol Sci. 2009;286(1-2):18-23. doi:10.1016/j.jns.2009.08.045
8. Al-Ani A, Chen JJ, Costello F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges. J Neurol. 2023;270(8):4132-4150. doi:10.1007/s00415-023-11737-8
9. Uzawa A, Oertel FC, Mori M, Paul F, Kuwabara S. NMOSD and MOGAD: an evolving disease spectrum. Nat Rev Neurol. 2024;20(10):602-619. doi:10.1038/s41582-024-01014-1
10. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. The Lancet Neurology 6.9 (2007): 805-815.
11. Ciccarelli O, Cohen JA, Reingold SC, et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol. 2019;18(2):185-197. doi:10.1016/S1474-4422(18)30460-5
12. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729
13. O’Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;60(4):382-387. doi:10.1136/jnnp.60.4.382